Leila Dorling
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Leila Dorling has a total of 249 co-authors. Here are the top co-authors by number of shared publications:
- Alison Margaret Dunning
University of Cambridge, Cambridge, United Kingdom
11 shared publications Douglas F. Easton
9 shared publicationsKamila Czene
9 shared publications- Brennan Decker
Foundation Medicine, Inc, Cambridge, MA
8 shared publications Craig Luccarini
8 shared publicationsJacques Simard
8 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
Towards a public-facing version of the CanRisk tool: Co-designing, developing and evaluating MyCanRisk
The CanRisk tool allows healthcare professionals to calculate validated multifactorial estimates of breast, ovarian, and prostate cancer risk. To support patient involvement in risk assessment, we co-designed a public-facing tool, MyCanRisk, which allows patients to collect and share risk information in advance of a clinical appointment, without generating risk estimates. This study describes the user-centred development of MyCanRisk and its initial evaluation. Development involved co-design workshops with patients, public contributors, healthcare professionals, and researchers, followed by iterative accessibility and usability testing against WCAG 2.2. Evaluation used a multi-methods design: 51 women with a family history of breast cancer completed MyCanRisk and, approximately two weeks later, a structured clinical-style interview. Agreement in risk categorisation was assessed using Cohen’s kappa. Semi-structured interviews with a purposive subsample (n=15) explored user experiences. MyCanRisk was perceived as accessible and easy to use. Agreement between MyCanRisk and structured interviews for risk categorisation was substantial (κ = 0.81, 95% CI 0.65–0.97). Discrepancies mainly reflected difficulties recalling detailed family history, such as ages at diagnosis and dates of birth/death. Participants valued the stepwise flow and asynchronous completion but reported challenges when their knowledge was incomplete. Suggested improvements included options to record approximate or unknown data and greater flexibility to update submissions. MyCanRisk has the potential to reduce data collection burden during clinical encounters, support patient preparation for risk assessment, and streamline cancer risk assessment pathways. With further refinement and testing in more diverse populations, it may facilitate earlier identification of individuals at increased cancer risk.
- 3 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
Open AccessTowards a public-facing version of the CanRisk tool: Co-designing, developing and evaluating MyCanRisk
The CanRisk tool allows healthcare professionals to calculate validated multifactorial estimates of breast, ovarian, and prostate cancer risk. To support patient involvement in risk assessment, we co-designed a public-facing tool, MyCanRisk, which allows patients to collect and share risk information in advance of a clinical appointment, without generating risk estimates. This study describes the user-centred development of MyCanRisk and its initial evaluation. Development involved co-design workshops with patients, public contributors, healthcare professionals, and researchers, followed by iterative accessibility and usability testing against WCAG 2.2. Evaluation used a multi-methods design: 51 women with a family history of breast cancer completed MyCanRisk and, approximately two weeks later, a structured clinical-style interview. Agreement in risk categorisation was assessed using Cohen’s kappa. Semi-structured interviews with a purposive subsample (n=15) explored user experiences. MyCanRisk was perceived as accessible and easy to use. Agreement between MyCanRisk and structured interviews for risk categorisation was substantial (κ = 0.81, 95% CI 0.65–0.97). Discrepancies mainly reflected difficulties recalling detailed family history, such as ages at diagnosis and dates of birth/death. Participants valued the stepwise flow and asynchronous completion but reported challenges when their knowledge was incomplete. Suggested improvements included options to record approximate or unknown data and greater flexibility to update submissions. MyCanRisk has the potential to reduce data collection burden during clinical encounters, support patient preparation for risk assessment, and streamline cancer risk assessment pathways. With further refinement and testing in more diverse populations, it may facilitate earlier identification of individuals at increased cancer risk.
- Open Access
- 27 April 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 60
A genome-wide association study on radiation induced fibrosis in breast cancer patients
- 27 April 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 60
Open AccessA genome-wide association study on radiation induced fibrosis in breast cancer patients
- Open Access
- 19 March 2026
- Published by Elsevier in SSRN Electronic Journal
A Genome-Wide Association Study on Radiation Induced Fibrosis in Breast Cancer Patients
Background and purposeRadiation-induced fibrosis affects women having undergone post-lumpectomy radiotherapy to a varying degree. Publications have identified Single Nucleotide Polymorphisms (SNPs) associated with fibrosis after radiotherapy in breast cancer patients. We aimed to identify new genetic variants in a cohort of early breast cancer patients representing two cohorts treated within the Danish Breast Cancer Group (DBCG) protocols.Patients/material and methodsThe genome-wide-association-analysis included 869 patients treated with lumpectomy and adjuvant radiotherapy in the DBCG trials hypo- versus normofractionated radiotherapy trial, DBCG-HYPO, and the DBCG partial versus whole breast irradiation trial, DBCG-PBI.Samples were genotyped using the Illumina Infinium OncoArray Bead Chip. Associations between common genetic variants and fibrosis grade 2 or 3 (LENT-SOMA) in a per-risk allele log-additive genetic model were tested in an exploratory genome-wide association study (GWAS). A genome-wide significance cut-off of P < 5x10-8 was applied.ResultsAn association reaching a P-value = 5.90 x10-8 after removal of principal component outliers was identified in a locus on chromosome 10. The strongest association was represented by the SNP rs75542274.InterpretationAn exploratory GWAS identified a locus on chromosome 10 reaching a near-significant genome-wide association with radiation-induced fibrosis. This finding must be tested in – or meta-analysed with - independent studies.
- 19 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA Genome-Wide Association Study on Radiation Induced Fibrosis in Breast Cancer Patients
Background and purposeRadiation-induced fibrosis affects women having undergone post-lumpectomy radiotherapy to a varying degree. Publications have identified Single Nucleotide Polymorphisms (SNPs) associated with fibrosis after radiotherapy in breast cancer patients. We aimed to identify new genetic variants in a cohort of early breast cancer patients representing two cohorts treated within the Danish Breast Cancer Group (DBCG) protocols.Patients/material and methodsThe genome-wide-association-analysis included 869 patients treated with lumpectomy and adjuvant radiotherapy in the DBCG trials hypo- versus normofractionated radiotherapy trial, DBCG-HYPO, and the DBCG partial versus whole breast irradiation trial, DBCG-PBI.Samples were genotyped using the Illumina Infinium OncoArray Bead Chip. Associations between common genetic variants and fibrosis grade 2 or 3 (LENT-SOMA) in a per-risk allele log-additive genetic model were tested in an exploratory genome-wide association study (GWAS). A genome-wide significance cut-off of P < 5x10-8 was applied.ResultsAn association reaching a P-value = 5.90 x10-8 after removal of principal component outliers was identified in a locus on chromosome 10. The strongest association was represented by the SNP rs75542274.InterpretationAn exploratory GWAS identified a locus on chromosome 10 reaching a near-significant genome-wide association with radiation-induced fibrosis. This finding must be tested in – or meta-analysed with - independent studies.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer
Genetic variants that increase breast cancer risk can be rare or common. This study tests whether the genetic risk stratification of breast cancer by rare and common variants in established loci can discriminate tumors with different biology, patient survival, and mode of detection. Multinomial logistic regression tested associations between genetic risk load [protein-truncating variant (PTV) carriership in 31 breast cancer predisposition genes—or polygenic risk score (PRS) using 162 single-nucleotide polymorphisms], tumor characteristics, and mode of detection (OR). Ten-year breast cancer–specific survival (HR) was estimated using Cox regression models. In this unselected cohort of 5,099 patients with breast cancer diagnosed in Sweden between 2001 and 2008, PTV carriers (n = 597) were younger and associated with more aggressive tumor phenotypes (ER-negative, large size, high grade, high proliferation, luminal B, and basal-like subtype) and worse outcome (HR, 1.65; 1.16–2.36) than noncarriers. After excluding 92 BRCA1/2 carriers, PTV carriership remained associated with high grade and worse survival (HR, 1.76; 1.21–2.56). In 5,007 BRCA1/2 noncarriers, higher PRS was associated with less aggressive tumor characteristics (ER-positive, PR-positive, small size, low grade, low proliferation, and luminal A subtype). Among patients with low mammographic density (<25%), non-BRCA1/2 PTV carriers were more often interval than screen-detected breast cancer (OR, 1.89; 1.12–3.21) than noncarriers. In contrast, higher PRS was associated with lower risk of interval compared with screen-detected cancer (OR, 0.77; 0.64–0.93) in women with low mammographic density. These findings suggest that rare and common breast cancer susceptibility loci are differentially associated with tumor characteristics, survival, and mode of detection.Significance: These findings offer the potential to improve screening practices for breast cancer by providing a deeper understanding of how risk variants affect disease progression and mode of detection. Cancer Res; 78(21); 6329–38. ©2018 AACR.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer
Genetic variants that increase breast cancer risk can be rare or common. This study tests whether the genetic risk stratification of breast cancer by rare and common variants in established loci can discriminate tumors with different biology, patient survival, and mode of detection. Multinomial logistic regression tested associations between genetic risk load [protein-truncating variant (PTV) carriership in 31 breast cancer predisposition genes—or polygenic risk score (PRS) using 162 single-nucleotide polymorphisms], tumor characteristics, and mode of detection (OR). Ten-year breast cancer–specific survival (HR) was estimated using Cox regression models. In this unselected cohort of 5,099 patients with breast cancer diagnosed in Sweden between 2001 and 2008, PTV carriers (n = 597) were younger and associated with more aggressive tumor phenotypes (ER-negative, large size, high grade, high proliferation, luminal B, and basal-like subtype) and worse outcome (HR, 1.65; 1.16–2.36) than noncarriers. After excluding 92 BRCA1/2 carriers, PTV carriership remained associated with high grade and worse survival (HR, 1.76; 1.21–2.56). In 5,007 BRCA1/2 noncarriers, higher PRS was associated with less aggressive tumor characteristics (ER-positive, PR-positive, small size, low grade, low proliferation, and luminal A subtype). Among patients with low mammographic density (<25%), non-BRCA1/2 PTV carriers were more often interval than screen-detected breast cancer (OR, 1.89; 1.12–3.21) than noncarriers. In contrast, higher PRS was associated with lower risk of interval compared with screen-detected cancer (OR, 0.77; 0.64–0.93) in women with low mammographic density. These findings suggest that rare and common breast cancer susceptibility loci are differentially associated with tumor characteristics, survival, and mode of detection.Significance: These findings offer the potential to improve screening practices for breast cancer by providing a deeper understanding of how risk variants affect disease progression and mode of detection. Cancer Res; 78(21); 6329–38. ©2018 AACR.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data Supplement 1 from Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer
EMethods describes additional details on the targeted sequencing and data processing methodology. Table S7 shows the associations between breast cancer genetic loci and breast cancer tumor characteristics diagnosed with breast cancer at below age 50. Table S8 shows the associations between breast cancer genetic loci and breast cancer tumor characteristics diagnosed with breast cancer at age 50 years and above. Figure S1 illustrates a flowchart summarizing the data processing work flow. Figure S2 shows a visual summary of the different rare variants called. Figure 3 shows the relationship between polygenic risk score (PRS) and protein-truncating variant carriership illustrated by boxplots. Figures S4-S6 show the results obtained by considering a subset of HBOC genes for the analyses on tumor characteristics, survival and mode of detection, respectively.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData Supplement 1 from Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer
EMethods describes additional details on the targeted sequencing and data processing methodology. Table S7 shows the associations between breast cancer genetic loci and breast cancer tumor characteristics diagnosed with breast cancer at below age 50. Table S8 shows the associations between breast cancer genetic loci and breast cancer tumor characteristics diagnosed with breast cancer at age 50 years and above. Figure S1 illustrates a flowchart summarizing the data processing work flow. Figure S2 shows a visual summary of the different rare variants called. Figure 3 shows the relationship between polygenic risk score (PRS) and protein-truncating variant carriership illustrated by boxplots. Figures S4-S6 show the results obtained by considering a subset of HBOC genes for the analyses on tumor characteristics, survival and mode of detection, respectively.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data Supplement 2 from Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer
Table S1 describes primer sequences and amplicon details. Table S2 summarizes percent callable bases and depth summary for the dataset. Table S3 lists the criteria for the hard filtering of variant calls. Table S4 shows a list of common variants used in the construction of the breast cancer polygenic risk scores. Table S5 shows a summary of 649 protein-truncating variants by gene in 597 unique samples. Table S6 tabulates protein-truncating variants and carrier counts.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData Supplement 2 from Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer
Table S1 describes primer sequences and amplicon details. Table S2 summarizes percent callable bases and depth summary for the dataset. Table S3 lists the criteria for the hard filtering of variant calls. Table S4 shows a list of common variants used in the construction of the breast cancer polygenic risk scores. Table S5 shows a summary of 649 protein-truncating variants by gene in 597 unique samples. Table S6 tabulates protein-truncating variants and carrier counts.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data Supplement 2 from Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer
Table S1 describes primer sequences and amplicon details. Table S2 summarizes percent callable bases and depth summary for the dataset. Table S3 lists the criteria for the hard filtering of variant calls. Table S4 shows a list of common variants used in the construction of the breast cancer polygenic risk scores. Table S5 shows a summary of 649 protein-truncating variants by gene in 597 unique samples. Table S6 tabulates protein-truncating variants and carrier counts.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData Supplement 2 from Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer
Table S1 describes primer sequences and amplicon details. Table S2 summarizes percent callable bases and depth summary for the dataset. Table S3 lists the criteria for the hard filtering of variant calls. Table S4 shows a list of common variants used in the construction of the breast cancer polygenic risk scores. Table S5 shows a summary of 649 protein-truncating variants by gene in 597 unique samples. Table S6 tabulates protein-truncating variants and carrier counts.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data Supplement 1 from Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer
EMethods describes additional details on the targeted sequencing and data processing methodology. Table S7 shows the associations between breast cancer genetic loci and breast cancer tumor characteristics diagnosed with breast cancer at below age 50. Table S8 shows the associations between breast cancer genetic loci and breast cancer tumor characteristics diagnosed with breast cancer at age 50 years and above. Figure S1 illustrates a flowchart summarizing the data processing work flow. Figure S2 shows a visual summary of the different rare variants called. Figure 3 shows the relationship between polygenic risk score (PRS) and protein-truncating variant carriership illustrated by boxplots. Figures S4-S6 show the results obtained by considering a subset of HBOC genes for the analyses on tumor characteristics, survival and mode of detection, respectively.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData Supplement 1 from Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer
EMethods describes additional details on the targeted sequencing and data processing methodology. Table S7 shows the associations between breast cancer genetic loci and breast cancer tumor characteristics diagnosed with breast cancer at below age 50. Table S8 shows the associations between breast cancer genetic loci and breast cancer tumor characteristics diagnosed with breast cancer at age 50 years and above. Figure S1 illustrates a flowchart summarizing the data processing work flow. Figure S2 shows a visual summary of the different rare variants called. Figure 3 shows the relationship between polygenic risk score (PRS) and protein-truncating variant carriership illustrated by boxplots. Figures S4-S6 show the results obtained by considering a subset of HBOC genes for the analyses on tumor characteristics, survival and mode of detection, respectively.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer
Genetic variants that increase breast cancer risk can be rare or common. This study tests whether the genetic risk stratification of breast cancer by rare and common variants in established loci can discriminate tumors with different biology, patient survival, and mode of detection. Multinomial logistic regression tested associations between genetic risk load [protein-truncating variant (PTV) carriership in 31 breast cancer predisposition genes—or polygenic risk score (PRS) using 162 single-nucleotide polymorphisms], tumor characteristics, and mode of detection (OR). Ten-year breast cancer–specific survival (HR) was estimated using Cox regression models. In this unselected cohort of 5,099 patients with breast cancer diagnosed in Sweden between 2001 and 2008, PTV carriers (n = 597) were younger and associated with more aggressive tumor phenotypes (ER-negative, large size, high grade, high proliferation, luminal B, and basal-like subtype) and worse outcome (HR, 1.65; 1.16–2.36) than noncarriers. After excluding 92 BRCA1/2 carriers, PTV carriership remained associated with high grade and worse survival (HR, 1.76; 1.21–2.56). In 5,007 BRCA1/2 noncarriers, higher PRS was associated with less aggressive tumor characteristics (ER-positive, PR-positive, small size, low grade, low proliferation, and luminal A subtype). Among patients with low mammographic density (<25%), non-BRCA1/2 PTV carriers were more often interval than screen-detected breast cancer (OR, 1.89; 1.12–3.21) than noncarriers. In contrast, higher PRS was associated with lower risk of interval compared with screen-detected cancer (OR, 0.77; 0.64–0.93) in women with low mammographic density. These findings suggest that rare and common breast cancer susceptibility loci are differentially associated with tumor characteristics, survival, and mode of detection.Significance: These findings offer the potential to improve screening practices for breast cancer by providing a deeper understanding of how risk variants affect disease progression and mode of detection. Cancer Res; 78(21); 6329–38. ©2018 AACR.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer
Genetic variants that increase breast cancer risk can be rare or common. This study tests whether the genetic risk stratification of breast cancer by rare and common variants in established loci can discriminate tumors with different biology, patient survival, and mode of detection. Multinomial logistic regression tested associations between genetic risk load [protein-truncating variant (PTV) carriership in 31 breast cancer predisposition genes—or polygenic risk score (PRS) using 162 single-nucleotide polymorphisms], tumor characteristics, and mode of detection (OR). Ten-year breast cancer–specific survival (HR) was estimated using Cox regression models. In this unselected cohort of 5,099 patients with breast cancer diagnosed in Sweden between 2001 and 2008, PTV carriers (n = 597) were younger and associated with more aggressive tumor phenotypes (ER-negative, large size, high grade, high proliferation, luminal B, and basal-like subtype) and worse outcome (HR, 1.65; 1.16–2.36) than noncarriers. After excluding 92 BRCA1/2 carriers, PTV carriership remained associated with high grade and worse survival (HR, 1.76; 1.21–2.56). In 5,007 BRCA1/2 noncarriers, higher PRS was associated with less aggressive tumor characteristics (ER-positive, PR-positive, small size, low grade, low proliferation, and luminal A subtype). Among patients with low mammographic density (<25%), non-BRCA1/2 PTV carriers were more often interval than screen-detected breast cancer (OR, 1.89; 1.12–3.21) than noncarriers. In contrast, higher PRS was associated with lower risk of interval compared with screen-detected cancer (OR, 0.77; 0.64–0.93) in women with low mammographic density. These findings suggest that rare and common breast cancer susceptibility loci are differentially associated with tumor characteristics, survival, and mode of detection.Significance: These findings offer the potential to improve screening practices for breast cancer by providing a deeper understanding of how risk variants affect disease progression and mode of detection. Cancer Res; 78(21); 6329–38. ©2018 AACR.
- Open Access
Breast cancer risks associated with missense variants in breast cancer susceptibility genes
BACKGROUND: Protein truncating variants in ATM, BRCA1, BRCA2, CHEK2 and PALB2 are associated with increased breast cancer risk, but risks associated with missense variants in these genes are uncertain. METHODS: Combining 59,639 breast cancer cases and 53,165 controls, we sampled training (80%) and validation (20%) sets to analyze rare missense variants in ATM (1,146 training variants), BRCA1 (644), BRCA2 (1,425), CHEK2 (325) and PALB2 (472). We evaluated breast cancer risks according to five in-silico prediction-of-deleteriousness algorithms, functional protein domain, and frequency, using logistic regression models and also mixture models in which a subset of variants was assumed to be risk-associated. RESULTS: The most predictive in-silico algorithms were Helix ( BRCA1, BRCA2 and CHEK2) and CADD ( ATM ). Increased risks appeared restricted to functional protein domains for ATM (FAT and PIK domains) and BRCA1 (RING and BRCT domains). For ATM, BRCA1 and BRCA2 , data were compatible with small subsets (approximately 7%, 2% and 0.6%, respectively) of rare missense variants giving similar risk to those of protein truncating variants in the same gene. For CHEK2 , data were more consistent with a large fraction (approximately 60%) of rare missense variants giving a lower risk (OR 1.75, 95% CI (1.47-2.08)) than CHEK2 protein truncating variants. There was little evidence for an association with risk for missense variants in PALB2 . The best fitting models were well calibrated in the validation set. CONCLUSIONS: These results will inform risk prediction models and the selection of candidate variants for functional assays, and could contribute to the clinical reporting of gene panel testing for breast cancer susceptibility.
Open AccessBreast cancer risks associated with missense variants in breast cancer susceptibility genes
BACKGROUND: Protein truncating variants in ATM, BRCA1, BRCA2, CHEK2 and PALB2 are associated with increased breast cancer risk, but risks associated with missense variants in these genes are uncertain. METHODS: Combining 59,639 breast cancer cases and 53,165 controls, we sampled training (80%) and validation (20%) sets to analyze rare missense variants in ATM (1,146 training variants), BRCA1 (644), BRCA2 (1,425), CHEK2 (325) and PALB2 (472). We evaluated breast cancer risks according to five in-silico prediction-of-deleteriousness algorithms, functional protein domain, and frequency, using logistic regression models and also mixture models in which a subset of variants was assumed to be risk-associated. RESULTS: The most predictive in-silico algorithms were Helix ( BRCA1, BRCA2 and CHEK2) and CADD ( ATM ). Increased risks appeared restricted to functional protein domains for ATM (FAT and PIK domains) and BRCA1 (RING and BRCT domains). For ATM, BRCA1 and BRCA2 , data were compatible with small subsets (approximately 7%, 2% and 0.6%, respectively) of rare missense variants giving similar risk to those of protein truncating variants in the same gene. For CHEK2 , data were more consistent with a large fraction (approximately 60%) of rare missense variants giving a lower risk (OR 1.75, 95% CI (1.47-2.08)) than CHEK2 protein truncating variants. There was little evidence for an association with risk for missense variants in PALB2 . The best fitting models were well calibrated in the validation set. CONCLUSIONS: These results will inform risk prediction models and the selection of candidate variants for functional assays, and could contribute to the clinical reporting of gene panel testing for breast cancer susceptibility.